Temporarily disabling a single protein inside our cells might be able to protect us from the common cold and other viral diseases. The protein, an actin histidine methyltransferase called SET domain containing 3 (SETD3), was identified in a CRISPR screen and confirmed to be essential to viral pathogenesis in cultured cells and mouse models. Curiously, when viruses use SETD3, they neglect the part needed for enzymatic function.
Purdue Pharma moved to carry out a more-than-$10 billion settlement with plaintiffs that include 24 U.S. states, more than 2,000 cities and counties, and five U.S. territories over claims that it illegally promoted its OxyContin opioid drug, contributing to the U.S. opioid epidemic by filing last night for reorganization under Chapter 11 of the U.S. Bankruptcy Code.
Bubbly extracellular vesicles could become mini treatment transporters, carrying a combination of therapeutic drugs and genes that target cancer cells and kill them, according to new research from Michigan State University and Stanford University.
BioNTech, the German developer of individualized treatments for cancer and other diseases that has raised more than $1 billion in capital as a privately-held company, has disclosed plans to go public by raising $100 million through an initial public offering.
This eBook sponsored by Agilent provides the latest recommendations from various leaders in immunotherapy research and their insights into exciting new developments. Their inspiration has guided and helped us compile these articles that showcase new analysis tools for scientists developing innovative cell-based solutions.
Atomwise and Jiangsu Hansoh Pharmaceutical Group—the Chinese company behind this year’s largest biopharma initial public offering (IPO)—said today they have launched an up-to-$1.5 billion collaboration to design and discover potential drug candidates for up to 11 undisclosed target proteins in cancer and “multiple” other therapeutic areas.
Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a gene that acts as a master regulator of schizophrenia during early human brain development, using computational tools designed to investigate gene transcription networks in large collections of brain tissues.
Washington University School of Medicine researchers found that the microbiomes of premature babies treated using antibiotics during the first few weeks of life continue to harbor fewer bacterial species associated with good health, and more unhealthy, and drug-resistant types of bacteria, even a year and half after they leave the hospital. The results suggest the possibility that antibiotic-related alterations to the infant microbiome might persist and increase the risk of health problems in adulthood.
Sumitomo Dainippon Pharma has agreed to acquire five of Roivant Sciences’ 20 companies or “vants”—as well as options to buy up to six more vants, and access to Roivant proprietary technology platforms—for $3 billion upfront.
Rutgers New Jersey Medical School research study reveals that reversible mutations in the M. tuberculosis glpK gene, a gene responsible for an important metabolic pathway, produce a reversible form of tolerance to most of the first-line drugs used to treat TB.
Please wait while you are redirected to the right page...